Stock Comparison

ALNY vs REGN

Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.

ALNY

Alnylam Pharmaceuticals Inc

Healthcare

REGN

Regeneron Pharmaceuticals Inc

Healthcare

Valuation

Market Cap

$30.70B

$80.55B

P/E (TTM)

40.0

19.4

Forward P/E

26.4

17.1

Price/Sales

6.4

5.2

Price/Book

22.7

2.5

EV/EBITDA

26.0

13.1

Dividend Yield

—

0.45%

Profitability

Net Margin

13.46%

29.65%

Operating Margin

17.54%

24.32%

Return on Equity

96.60%

14.00%

Return on Assets

12.30%

6.53%

Growth (YoY)

Revenue Growth

66.90%

16.70%

Earnings Growth

0.00%

-4.50%

Price & Risk

Beta

0.3

0.2

52-Week High

$491.22

$810.12

52-Week Low

$205.48

$553.38

Analyst Target

$375.76

$833.54

Compare ALNY and REGN your own way

Try mrmarket.ai free

Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.